Pyridazine derivatives

US7129241B2 · kind B2 · utility

Assignee

• Merck Patentgesellschaft · DE

Inventors

• Hans-Michael Eggenweiler · Darmstadt, DE
• Michael Wolf · Darmstadt, DE

Key dates

• Filing date: May 12, 2003
• Grant date: Oct 31, 2006
• Expiry date: May 12, 2023

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D401/12
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Pyridazine derivatives of the formula (I) act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS